Why you won't see a semaglutide advertisement on TV — and what that means for you

The biggest misconception: 'it's just marketing rules, everyone ignores them'

A common assumption is that medicines advertising rules are background noise that brands quietly sidestep. They are not. The Human Medicines Regulations 2012 make promoting a Prescription-Only Medicine to the public a criminal offence. That covers television, print, social media, influencer partnerships and paid search ads. It covers both the brand name Wegovy and the generic name semaglutide. Renaming the active ingredient in a caption does not make a promotional post compliant.

The MHRA is unambiguous: GLP-1 receptor agonists are not assessed for rapid or cosmetic weight loss, and content framing them that way (regardless of format) runs directly against that position. When the regulator says 'not assessed for quick weight loss', it means clinical evidence was gathered in controlled trials over 68–72 weeks, with lifestyle support, not a six-week aesthetic treatment. If you want to understand what a lawful Wegovy advert can and cannot say, the distinction between promotion and education is the single most important line to understand.

What IS lawful is educational content: explaining how semaglutide works, who may be clinically suitable, what trial data shows, what the NHS pathway looks like, and what the prescribing process involves. The test is simple, does the content promote the medicine, or does it inform the reader? Promotion pushes a purchase decision. Education supports an informed conversation with a prescriber.

Why social media is where semaglutide advertising rules are most visibly broken

A question our prescribers hear most weeks is some version of: "I saw it on TikTok, does that make it safe to buy?" Social media has become the primary channel through which unlicensed sellers reach potential customers, precisely because enforcement is slower there than in broadcast advertising. Influencer posts, before-and-after reels and countdown offers for semaglutide injections circulate constantly, most without any mention of prescription requirements or clinical assessment.

The MHRA has linked this promotional environment directly to the counterfeit supply chain. Fake pens seized in the UK (including counterfeit tirzepatide pens found at an illicit manufacturing site in October 2025) were overwhelmingly marketed through social channels, often with price incentives and urgency messaging that would be impossible under lawful medicines advertising standards. In 2025 alone, enforcement activity accounted for roughly 20 million doses of illegally traded weight-loss medicines with a street value of around £45 million.

If you are researching semaglutide advertising standards because you have seen something that looked promotional rather than educational, the MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk accepts reports of suspected illegal advertising as well as adverse reactions. That is a genuine public-health function, not just a complaints line.

What compliant semaglutide content actually covers, and what it leaves out

Responsible content about semaglutide answers factual questions: what kind of medicine it is, what the licensed indications are, what the clinical trial results showed, how the titration schedule is structured, what common side effects look like, and how to access it lawfully through a prescribing service. None of that requires promoting the product.

What compliant content does not do: quote per-pen prices as an incentive, offer discount codes or vouchers tied to the medicine, make outcome guarantees, use urgency language around stock or availability, or present the medicine as suitable for everyone who wants to lose weight quickly. The clinical reality (that semaglutide is suitable only for adults meeting specific BMI and clinical criteria, assessed individually by a prescriber) is both the legal requirement and the honest answer.

For a fuller picture of how Wegovy works and what the prescribing process involves, the Wegovy treatment overview on this site is written to the same standard: educational, cited, and prescriber-reviewed. Similarly, if cost is part of your thinking, our guide to Wegovy cost in the UK explains market pricing honestly without promotional framing.

What this means if you are considering semaglutide treatment

The advertising restrictions exist because semaglutide is a clinically significant medicine, not a consumer product. The route to it runs through a clinical assessment, a prescriber reviews your health history, current medicines, BMI, and any relevant conditions before deciding whether it is appropriate for you. That process is the safeguard the system is built around.

A semaglutide treatment plan begins at a low starter dose and is titrated over months by a prescriber, with reviews at each stage. The side-effect profile (predominantly gastrointestinal, typically settling as your body adjusts) is something a prescriber discusses with you before you start, not something you should discover from a social post after buying from an unverified source.

At nume, every consultation is read by a GPhC-registered Independent Prescriber, on the same day. Our pharmacy is registered with the GPhC (premises number 9012878, verifiable at pharmacyregulation.org), and medicines move through the licensed UK supply chain. If you would like to understand whether you are clinically suitable, you can check your eligibility through a free consultation, no obligation, no urgency, just a proper clinical conversation.